Background and Objectives: Acute kidney injury (AKI) is a common complication among patients with COVID-19 and acute respiratory distress syndrome. Reports suggest that COVID-19 confers a pro-thrombotic state, which presents challenges in maintaining hemofilter patency and delivering continuous renal replacement therapy (CRRT). We present our initial experience with CRRT in critically ill patients with COVID-19, emphasizing circuit patency and the association between fluid balance during CRRT and respiratory parameters. Design, Setting, Participants, and Measurements: Retrospective chart review of 32 consecutive patients with COVID-19 and AKI managed with continuous venovenous hemodiafiltration with regional citrate anticoagulation (CVVHDF-RCA) according to the University of Michigan protocol. Primary outcome was mean CRRT circuit life per patient during the first 7 days of CRRT. We used simple linear regression to assess the relationship between patient characteristics and filter life. We also explored the relationship between fluid balance on CRRT and respiratory parameters using repeated measures modeling. Results: Patients’ mean age was 54.8 years and majority were Black (75%). Comorbidities included hypertension (90.6%), obesity (70.9%) diabetes (56.2%), and chronic kidney disease (40.6%). Median CRRT circuit life was 53.5 [interquartile range 39.1–77.6] hours. There was no association between circuit life and inflammatory or pro-thrombotic laboratory values (ferritin p = 0.92, C-reactive protein p = 0.29, D-dimer p = 0.24), or with systemic anticoagulation (p = 0.37). Net daily fluid removal during the first 7 days of CRRT was not associated with daily (closest recorded values to 20:00) PaO2/FIO2 ratio (p = 0.21) or positive end-expiratory pressure requirements (p = 0.47). Conclusions: We achieved adequate CRRT circuit life in COVID-19 patients using an established CVVHDF-RCA protocol. During the first 7 days of CRRT therapy, cumulative fluid balance was not associated with improvements in respiratory parameters, even after accounting for baseline fluid balance.

1.
Guan
WJ
,
Ni
ZY
,
Hu
Y
,
Liang
WH
,
Ou
CQ
,
He
JX
,
Clinical characteristics of coronavirus disease 2019 in China
.
N Engl J Med
.
2020
;
382
(
18
):
1708
20
. .
2.
Hirsch
JS
,
Ng
JH
,
Ross
DW
,
Sharma
P
,
Shah
HH
,
Barnett
RL
,
Acute kidney injury in patients hospitalized with COVID-19
.
Kidney Int
.
2020
;
98
(
1
):
209
18
. .
3.
Mohamed
MMB
,
Lukitsch
I
,
Torres-Ortiz
AE
,
Walker
JB
,
Varghese
V
,
HErnandez-Arroyo
CF
,
Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans
.
Kidney360
.
2020
;
1
(
7
):
614
22
.
4.
Gupta
S
,
Hayek
SS
,
Wang
W
,
Chan
L
,
Mathews
KS
,
Melamed
ML
,
Factors associated with death in critically Ill patients with coronavirus disease 2019 in the US
.
JAMA Intern Med
.
2020
;
180
(
11
):
1436
47
.
5.
Fisher
M
,
Prudhvi
K
,
Brogan
M
,
Golestaneh
L
.
Providing care to patients with acute kidney injury and COVID-19 infection: experience of front line nephrologists in New York
.
Kidney360.
2020
;
1
(
6
):
544
8
.
6.
Division of Nephrology, Columbia University Vagelos College of Physicians
.
Disaster response to the COVID-19 pandemic for patients with kidney disease in New York City
.
J Am Soc Nephrol
.
2020
;
31
(
7
):
1371
9
. .
7.
Zhang
Y
,
Xiao
M
,
Zhang
S
,
Xia
P
,
Cao
W
,
Jiang
W
,
Coagulopathy and antiphospholipid antibodies in patients with covid-19
.
N Engl J Med
.
2020
;
382
(
17
):
e38
. .
8.
Paranjpe
I
,
Fuster
V
,
Lala
A
,
Russak
A
,
Glicksberg
BS
,
Levin
MA
,
Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19
.
J Am Coll Cardiol
.
2020
;
76
(
1
):
122
4
.
9.
Mohamed MMB
,
Lukitsch
I
,
Torres-Ortiz
AE
,
Walker
JB
,
Varghese
V
,
HErnandez-Arroyo
CF
,
Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans
.
Kidney360
.
2020
;
1
(
5
).
10.
Pandharipande
PP
,
Girard
TD
,
Jackson
JC
,
Morandi
A
,
Thompson
JL
,
Pun
BT
,
Long-term cognitive impairment after critical illness
.
N Engl J Med
.
2013
;
369
(
14
):
1306
16
. .
11.
Goldfarb
DS
,
Benstein
JA
,
Zhdanova
O
,
Hammer
E
,
Block
CA
,
Caplin
NJ
,
Impending shortages of kidney replacement therapy for COVID-19 patients
.
Clin J Am Soc Nephrol
.
2020
;
15
(
6
):
880
2
.
12.
Nephrology Journal Club blog (Neph JC). Acute Kidney Injury. Available from: http://www.nephjc.com/news/covidaki. Accessed 2020 Jul 25.
13.
Schilder
L
,
Nurmohamed
SA
,
Bosch
FH
,
Purmer
IM
,
den Boer
SS
,
Kleppe
CG
,
Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial
.
Crit Care
.
2014
;
18
(
4
):
472
. .
14.
Stucker
F
,
Ponte
B
,
Tataw
J
,
Martin
PY
,
Wozniak
H
,
Pugin
J
,
Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial
.
Crit Care
.
2015
;
19
:
91
. .
15.
Zarbock
A
,
Küllmar
M
,
Kindgen-Milles
D
,
Wempe
C
,
Gerss
J
,
Brandenburger
T
,
Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically Ill patients with acute kidney injury: a randomized clinical trial
.
JAMA
.
2020
;
324
(
16
):
1629
39
. .
16.
Swartz
R
,
Pasko
D
,
O’Toole
J
,
Starmann
B
.
Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation
.
Clin Nephrol
.
2004
;
61
(
2
):
134
43
. .
17.
National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network
;
Wiedemann
HP
,
Wheeler
AP
,
Bernard
GR
,
Thompson
BT
,
Hayden
D
,
Comparison of two fluid-management strategies in acute lung injury
.
N Engl J Med
.
2006
;
354
(
24
):
2564
75
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.